CytoReason, a pioneer in computational disease modeling, expanded its collaboration with Sanofi. The multiyear collaboration will further Sanofi’s target discovery efforts via CytoReason’s AI platform in the field of inflammatory bowel disease (IBD), to identify patient subtypes and pair them with IBD targets. In 2021, the companies initiated a project with Sanofi using cell-centered models to suggest mechanistic insights for asthma endotypes.   Under the terms of the expanded agreement, Sanof...